![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: VDAC3 |
Gene summary for VDAC3 |
![]() |
Gene information | Species | Human | Gene symbol | VDAC3 | Gene ID | 7419 |
Gene name | voltage dependent anion channel 3 | |
Gene Alias | HD-VDAC3 | |
Cytomap | 8p11.21 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q9Y277 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
7419 | VDAC3 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.95e-05 | 1.93e-01 | 0.0155 |
7419 | VDAC3 | HTA11_2487_2000001011 | Human | Colorectum | SER | 1.47e-03 | 3.71e-01 | -0.1808 |
7419 | VDAC3 | HTA11_1938_2000001011 | Human | Colorectum | AD | 4.77e-17 | 6.63e-01 | -0.0811 |
7419 | VDAC3 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.44e-24 | 7.99e-01 | -0.1088 |
7419 | VDAC3 | HTA11_347_2000001011 | Human | Colorectum | AD | 4.06e-24 | 6.80e-01 | -0.1954 |
7419 | VDAC3 | HTA11_411_2000001011 | Human | Colorectum | SER | 4.06e-02 | 5.62e-01 | -0.2602 |
7419 | VDAC3 | HTA11_83_2000001011 | Human | Colorectum | SER | 6.79e-09 | 5.12e-01 | -0.1526 |
7419 | VDAC3 | HTA11_696_2000001011 | Human | Colorectum | AD | 4.95e-05 | 3.30e-01 | -0.1464 |
7419 | VDAC3 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.55e-08 | 4.04e-01 | -0.059 |
7419 | VDAC3 | HTA11_5212_2000001011 | Human | Colorectum | AD | 7.35e-03 | 5.48e-01 | -0.2061 |
7419 | VDAC3 | HTA11_5216_2000001011 | Human | Colorectum | SER | 8.44e-03 | 5.94e-01 | -0.1462 |
7419 | VDAC3 | HTA11_546_2000001011 | Human | Colorectum | AD | 8.94e-05 | 3.83e-01 | -0.0842 |
7419 | VDAC3 | HTA11_7862_2000001011 | Human | Colorectum | AD | 3.52e-04 | 4.15e-01 | -0.0179 |
7419 | VDAC3 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.37e-04 | 2.65e-01 | 0.096 |
7419 | VDAC3 | HTA11_4255_2000001011 | Human | Colorectum | SER | 4.00e-04 | 4.46e-01 | 0.0446 |
7419 | VDAC3 | HTA11_8622_2000001021 | Human | Colorectum | SER | 3.93e-02 | 3.09e-01 | 0.0528 |
7419 | VDAC3 | HTA11_7663_2000001011 | Human | Colorectum | SER | 7.27e-04 | 4.63e-01 | 0.0131 |
7419 | VDAC3 | HTA11_10623_2000001011 | Human | Colorectum | AD | 6.48e-09 | 6.39e-01 | -0.0177 |
7419 | VDAC3 | HTA11_6801_2000001011 | Human | Colorectum | SER | 4.26e-09 | 7.40e-01 | 0.0171 |
7419 | VDAC3 | HTA11_7696_3000711011 | Human | Colorectum | AD | 6.81e-04 | 3.68e-01 | 0.0674 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0015698 | Colorectum | AD | inorganic anion transport | 52/3918 | 180/18723 | 6.83e-03 | 4.22e-02 | 52 |
GO:0120032 | Colorectum | AD | regulation of plasma membrane bounded cell projection assembly | 53/3918 | 186/18723 | 8.51e-03 | 4.97e-02 | 53 |
GO:01200321 | Colorectum | SER | regulation of plasma membrane bounded cell projection assembly | 43/2897 | 186/18723 | 3.82e-03 | 3.16e-02 | 43 |
GO:0060491 | Colorectum | SER | regulation of cell projection assembly | 43/2897 | 188/18723 | 4.68e-03 | 3.70e-02 | 43 |
GO:01200322 | Colorectum | MSS | regulation of plasma membrane bounded cell projection assembly | 51/3467 | 186/18723 | 1.78e-03 | 1.58e-02 | 51 |
GO:00604911 | Colorectum | MSS | regulation of cell projection assembly | 51/3467 | 188/18723 | 2.28e-03 | 1.87e-02 | 51 |
GO:00156981 | Colorectum | FAP | inorganic anion transport | 38/2622 | 180/18723 | 5.73e-03 | 3.67e-02 | 38 |
GO:01200323 | Colorectum | FAP | regulation of plasma membrane bounded cell projection assembly | 39/2622 | 186/18723 | 5.84e-03 | 3.73e-02 | 39 |
GO:00604912 | Colorectum | FAP | regulation of cell projection assembly | 39/2622 | 188/18723 | 7.01e-03 | 4.29e-02 | 39 |
GO:190211514 | Esophagus | ESCC | regulation of organelle assembly | 116/8552 | 186/18723 | 3.15e-06 | 3.53e-05 | 116 |
GO:006049118 | Esophagus | ESCC | regulation of cell projection assembly | 110/8552 | 188/18723 | 2.60e-04 | 1.58e-03 | 110 |
GO:012003218 | Esophagus | ESCC | regulation of plasma membrane bounded cell projection assembly | 108/8552 | 186/18723 | 4.37e-04 | 2.46e-03 | 108 |
GO:1902115 | Liver | Cirrhotic | regulation of organelle assembly | 66/4634 | 186/18723 | 6.66e-04 | 5.04e-03 | 66 |
GO:01200326 | Liver | Cirrhotic | regulation of plasma membrane bounded cell projection assembly | 63/4634 | 186/18723 | 3.16e-03 | 1.78e-02 | 63 |
GO:00604915 | Liver | Cirrhotic | regulation of cell projection assembly | 63/4634 | 188/18723 | 4.17e-03 | 2.22e-02 | 63 |
GO:19021151 | Liver | HCC | regulation of organelle assembly | 110/7958 | 186/18723 | 3.30e-06 | 4.34e-05 | 110 |
GO:006049112 | Liver | HCC | regulation of cell projection assembly | 101/7958 | 188/18723 | 1.20e-03 | 6.69e-03 | 101 |
GO:012003212 | Liver | HCC | regulation of plasma membrane bounded cell projection assembly | 100/7958 | 186/18723 | 1.23e-03 | 6.81e-03 | 100 |
GO:19021155 | Oral cavity | OSCC | regulation of organelle assembly | 109/7305 | 186/18723 | 4.54e-08 | 8.45e-07 | 109 |
GO:006049110 | Oral cavity | OSCC | regulation of cell projection assembly | 100/7305 | 188/18723 | 5.27e-05 | 4.38e-04 | 100 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa052038 | Oral cavity | OSCC | Viral carcinogenesis | 124/3704 | 204/8465 | 5.57e-07 | 3.28e-06 | 1.67e-06 | 124 |
hsa046218 | Oral cavity | OSCC | NOD-like receptor signaling pathway | 108/3704 | 186/8465 | 5.13e-05 | 2.07e-04 | 1.05e-04 | 108 |
hsa0501725 | Oral cavity | OSCC | Spinocerebellar ataxia | 86/3704 | 143/8465 | 5.21e-05 | 2.08e-04 | 1.06e-04 | 86 |
hsa0421620 | Oral cavity | OSCC | Ferroptosis | 29/3704 | 41/8465 | 4.26e-04 | 1.30e-03 | 6.60e-04 | 29 |
hsa05012113 | Oral cavity | OSCC | Parkinson disease | 188/3704 | 266/8465 | 1.82e-19 | 1.52e-17 | 7.75e-18 | 188 |
hsa05016112 | Oral cavity | OSCC | Huntington disease | 204/3704 | 306/8465 | 1.70e-16 | 7.13e-15 | 3.63e-15 | 204 |
hsa05010112 | Oral cavity | OSCC | Alzheimer disease | 244/3704 | 384/8465 | 1.18e-15 | 3.60e-14 | 1.83e-14 | 244 |
hsa05022112 | Oral cavity | OSCC | Pathways of neurodegeneration - multiple diseases | 292/3704 | 476/8465 | 1.60e-15 | 4.47e-14 | 2.28e-14 | 292 |
hsa05020112 | Oral cavity | OSCC | Prion disease | 181/3704 | 273/8465 | 2.05e-14 | 5.30e-13 | 2.70e-13 | 181 |
hsa05166113 | Oral cavity | OSCC | Human T-cell leukemia virus 1 infection | 150/3704 | 222/8465 | 3.68e-13 | 7.26e-12 | 3.70e-12 | 150 |
hsa05208114 | Oral cavity | OSCC | Chemical carcinogenesis - reactive oxygen species | 150/3704 | 223/8465 | 6.45e-13 | 1.20e-11 | 6.11e-12 | 150 |
hsa04218110 | Oral cavity | OSCC | Cellular senescence | 112/3704 | 156/8465 | 8.04e-13 | 1.42e-11 | 7.21e-12 | 112 |
hsa05415113 | Oral cavity | OSCC | Diabetic cardiomyopathy | 131/3704 | 203/8465 | 1.33e-09 | 1.49e-08 | 7.57e-09 | 131 |
hsa0516113 | Oral cavity | OSCC | Hepatitis B | 103/3704 | 162/8465 | 2.34e-07 | 1.51e-06 | 7.69e-07 | 103 |
hsa0520314 | Oral cavity | OSCC | Viral carcinogenesis | 124/3704 | 204/8465 | 5.57e-07 | 3.28e-06 | 1.67e-06 | 124 |
hsa0462113 | Oral cavity | OSCC | NOD-like receptor signaling pathway | 108/3704 | 186/8465 | 5.13e-05 | 2.07e-04 | 1.05e-04 | 108 |
hsa05017111 | Oral cavity | OSCC | Spinocerebellar ataxia | 86/3704 | 143/8465 | 5.21e-05 | 2.08e-04 | 1.06e-04 | 86 |
hsa04216110 | Oral cavity | OSCC | Ferroptosis | 29/3704 | 41/8465 | 4.26e-04 | 1.30e-03 | 6.60e-04 | 29 |
hsa05012210 | Oral cavity | LP | Parkinson disease | 166/2418 | 266/8465 | 2.02e-31 | 3.36e-29 | 2.17e-29 | 166 |
hsa0501629 | Oral cavity | LP | Huntington disease | 172/2418 | 306/8465 | 6.31e-25 | 5.25e-23 | 3.39e-23 | 172 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
VDAC3 | SNV | Missense_Mutation | rs551923370 | c.353N>T | p.Ser118Phe | p.S118F | Q9Y277 | protein_coding | deleterious(0.01) | possibly_damaging(0.66) | TCGA-AR-A5QP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
VDAC3 | SNV | Missense_Mutation | rs752791425 | c.511N>A | p.Ala171Thr | p.A171T | Q9Y277 | protein_coding | tolerated(0.07) | benign(0.02) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
VDAC3 | SNV | Missense_Mutation | c.673N>G | p.Lys225Glu | p.K225E | Q9Y277 | protein_coding | deleterious(0) | possibly_damaging(0.551) | TCGA-AA-3941-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
VDAC3 | SNV | Missense_Mutation | novel | c.104N>A | p.Ser35Tyr | p.S35Y | Q9Y277 | protein_coding | deleterious(0.03) | benign(0.015) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
VDAC3 | SNV | Missense_Mutation | novel | c.170N>A | p.Gly57Asp | p.G57D | Q9Y277 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
VDAC3 | SNV | Missense_Mutation | novel | c.104N>A | p.Ser35Tyr | p.S35Y | Q9Y277 | protein_coding | deleterious(0.03) | benign(0.015) | TCGA-A5-A0GG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
VDAC3 | SNV | Missense_Mutation | novel | c.391N>A | p.Asp131Asn | p.D131N | Q9Y277 | protein_coding | tolerated(0.08) | possibly_damaging(0.635) | TCGA-A5-A2K7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | taxol | SD |
VDAC3 | SNV | Missense_Mutation | rs775234791 | c.442N>A | p.Glu148Lys | p.E148K | Q9Y277 | protein_coding | tolerated(0.25) | benign(0.175) | TCGA-B5-A11N-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
VDAC3 | SNV | Missense_Mutation | novel | c.104C>A | p.Ser35Tyr | p.S35Y | Q9Y277 | protein_coding | deleterious(0.03) | benign(0.015) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
VDAC3 | SNV | Missense_Mutation | novel | c.485N>C | p.Lys162Thr | p.K162T | Q9Y277 | protein_coding | deleterious(0.01) | possibly_damaging(0.769) | TCGA-EO-A3AY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
7419 | VDAC3 | KINASE | OLESOXIME | OLESOXIME | ||
7419 | VDAC3 | KINASE | PRLX93936 |
Page: 1 |